Slide 1: 2023 Sustainability Highlights
2023 Sustainability Highlights Conference call for investors and analysts March 2024
Slide 2: Forward-looking statements
Forward-looking statements In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter ‘the Group’) provides the following cautionary statement: this document contains certain forward-looking statements wit
Slide 3: Sustainability at AstraZeneca
Sustainability at AstraZeneca Pam Cheng E X E C U T I V E V I C E P R E S I D E N T, G L O B A L O P E R AT I O N S , I N F O R M AT I O N T E C H N O L O G Y A N D C H I E F S U S TA I N A B I L I T Y O F F I C E R 3
Slide 4: Sustainability Governance at AstraZeneca
Sustainability Governance at AstraZeneca Board of Directors – Delegated Committees Board Audit Committee Sustainability Committee Remuneration Committee Philip Broadley Nazneen Rahman Sheri McCoy Senior Independent Non-Executive Director of the Board, Non-Executive Director of the Board, Non-Executi
Slide 5: 2023 Sustainability highlights
2023 Sustainability highlights Progress on our overall Access to Healthcare Environmental Protection Ethics and Transparency strategy includes: 15 127,384 67.6% 50.1% public and private sector organisations healthcare workers and others trained1 reduction in Scope 1 and Scope 2 senior middle managem
Slide 6: Access to Healthcare
Access to Healthcare Securing a future of access to affordable, sustainable, and innovative healthcare Progress in 2023 Strategy update Our ambition: TARGETS: to promote prevention, increase access to life-saving treatments 66.4m People reached1 50m Broadening beyond by 2025 philanthropic programmes
Slide 7: Access to Healthcare: Partnering to drive focused interventions and policy change
Access to Healthcare Partnering to drive focused interventions and policy change Partnership for Health System Sustainability and Resilience (PHSSR) Access in Action: PHSSR impact case studies European Union Japan Brazil Committed to collaborating across SECTORS and BORDERS Acting Early on NCDs Digi
Slide 8: Access to Healthcare – Clinical Trial Diversity
Access to Healthcare – Clinical Trial Diversity Committed to designing clinical trials with equity at the forefront Focused on: Progress in 2023 Committed to: PUBLICATION including retrospective analysis of Designing 246 clinical trials in the US INCLUSIVE TRIALS PATIENT CENTRICITY Launch of interna
Slide 9: Environmental Protection
Environmental Protection Driving bold decarbonisation through Ambition Zero Carbon Scope 1 Scope 2 Scope 3 Scope 1 & 2 Scope 3 Total Revenue vs. Scope 1 & 2 emissions TARGETS: TARGETS: Of suppliers with 68% Reduce Scope 1 & 2 98% $50,000 700,000 60% science-based targets 20251 emissions vs. 2015 by
Slide 10: Biodiversity at AstraZeneca
Biodiversity at AstraZeneca Integrating a circular economy approach across our value chain Circular economy Biodiversity AZ Forest bringing nature more prominently maximising the co-benefits into decision-making of reforestation Incorporate principles of the circulate economy By END of 2024: TARGETS
Slide 11: Ethics and Transparency
Ethics and Transparency Ethical and transparent business, delivering positive impacts for patients and society Progress in 2023 Our ambition: WORKFORCE HEALTH and SAFETY INCLUSION and DIVERSITY TARGETS: ensuring ethical, open and Launch ex-US supplier Reduce inclusive behaviour across our organisati
Slide 12: Ethics and Transparency: Cybersecurity, data protection and AI
Ethics and Transparency Cybersecurity, data protection and working ethically with AI Data protection Use of AI in healthcare 2023 WHITE PAPER: Protecting enterprise cybersecurity via: regulations on AI in healthcare TRUST BY DESIGN CYBER AWARENESS TRAINING Using ethical data and AI systems AI POWERE
Slide 13: Sustainability Reporting
Sustainability Reporting Preparing for an evolving regulatory landscape Regulatory updates EU Corporate Sustainability Reporting Directive (CSRD) STANDARDS and GAP ASSESSMENT DOUBLE FRAMEWORKS MATERIALITY European Sustainability Reporting Standards (ESRS) ― Actively monitoring ― Evaluating external
Slide 14: Q&A Session
Q&A Session with Sustainability Leadership Team Pam Cheng EXECUTIVE VICE PRESIDENT, GLOBAL Stefan Weber OPERATIONS, INFORMATION VICE PRESIDENT POLICY, PATIENT TECHNOLOGY AND CHIEF ADVOCACY AND HEALTH EQUITY SUSTAINABILITY OFFICER Juliette White Beth Hamilton VICE PRESIDENT, GLOBAL SHE AND VICE PRESI
Slide 15: Use of AstraZeneca slides from conference calls and webcasts
Use of AstraZeneca slides from conference calls and webcasts The AstraZeneca webcast, conference call and presentation slides (together the ‘AstraZeneca materials’) are for your personal, non-commercial use only. You may not copy, reproduce, republish, post, broadcast, transmit, make available to th